Videos

O’Leary discusses safety related to instillation of the Penuma penile enhancement implant.

Darolutamide is currently approved for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

The immunotherapy/TKI combination significantly improved overall survival versus sunitinib.

“I find [the Prolaris test] to be a very helpful clinical tool,” says Jonathan D. Tward, MD, PhD.

Hear from key opinion leaders in the urology space as they discuss 2 complex cases across the multidisciplinary approach for an incidentally discovered adrenal mass and localized, high-risk prostate cancer with oligometastasis at diagnosis.

Boorjian anticipates research with nadofaragene firadenovec in settings beyond BCG-unresponsive non-muscle invasive bladder cancer.

O’Leary is 1 of 10 surgeons in the United States capable of performing the surgery to install the FDA-cleared Penuma penile enhancement implant.

Motzer highlights the overall survival benefit achieved with the combination of the PD-1 inhibitor and the multikinase inhibitor versus standard sunitinib in the phase 3 CLEAR trial.

“The biggest risk that our patients face is a severe COVID-19 episode,” says Kutikov.

“One of the things that distinguishes this treatment is its patient and provider ease of delivery,” says Boorjian.

The ongoing trial is enrolling patients at 62 locations in the United States and worldwide.

The FDA recently approved a less-frequent, fixed dose of durvalumab at 1500 mg every 4 weeks for use in patients with metastatic urothelial carcinoma.

The FDA approved darolutamide in July 2019 for the treatment of patients with nonmetastatic castration-resistant prostate cancer, based on findings from the phase 3 ARAMIS trial.

“We continue to see a building story of benefit of statin medications in men who have prostate cancer,” says Robert J. Hamilton, MD, MPH.

Chris Du, MD, discusses findings from a study published in Neurourology and Urodynamics.

Investigators evaluated uropathogen prevalence and antibiotic resistance in a urogynecologic patient population.

Hear from key opinion leaders in the urology space as they discuss 2 complex cases across the multidisciplinary approach in upper tract urothelial carcinoma and an incidentally discovered renal mass.

Attorney Kenton H. Steele, Esq, discusses his recent Urology Times® column.

Rena Malik, MD, discusses findings from a recent Urology Practice study.

Researchers evaluated the use of interprofessional consultations within the specialty of urology.

Adam J. Gadzinski, MD, MS, highlights positive outcomes of telemedicine multidisciplinary urologic cancer clinics implemented by the University of Washington/Seattle Cancer Care Alliance.

Only 5% of websites studied discuss risks of treatments, investigators found.

Ramaprasad Srinivasan, MD, PhD, provides background on the prognosis and treatment of patients with Von Hippel-Lindau–associated renal cell carcinoma and highlights the novel agent MK-6482.

Vikram M. Narayan, MD, discusses the high complete response rate and manageable safety profile with nadofaragene firadenovec in BCG-unresponsive non-muscle invasive bladder cancer.